Cobra Biologics Appoints CSO
This article was originally published in Scrip
International contract manufacturing organization Cobra Biologics has named Dr Daniel C Smith chief scientific officer. He will be responsible for enhancing Cobra's DNA, virus, microbial and mammalian proteins research and development platforms. Prior to joining the Sweden and UK-situated company Dr Smith was a knowledge transfer manager with bioProcessUK at the HealthTech and Medicines Knowledge Transfer Network.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.